|Bid||22.01 x 1000|
|Ask||22.03 x 100|
|Day's Range||20.36 - 22.23|
|52 Week Range||6.70 - 22.23|
|PE Ratio (TTM)||76.66|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.75|
NEW YORK, Jan. 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Perry ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Corcept Therapeutics, Inc. Here are 5 ETFs with the largest exposure to CORT-US. Comparing the performance and risk of Corcept Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
TherapeuticsMD (TXMD) announces submission of NDA to the FDA seeking approval of TX-001HR to treat vasomotor symptoms in post-menopausal women.
In September 2017, Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its latest earnings update, which showed that the company finally turned profitable after negative earnings on average over the past couple ofRead More...
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.
The FDA grants a fast track status to Insys' (INSY) cannabidiol oral solution for Prader-Willi syndrome. The company also plans to move the candidate into clinical development in first-quarter 2018.
Alexion's (ALXN) announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan approved the label expansion of Soliris for the treatment of patients with generalized myasthenia gravis (gMG).
Merck's (MRK) three diabetes drugs get FDA approval as adjunct treatment to diet and exercise to improve glycemic control in patients with diabetes mellitus.
BioMarin (BMRN) extended the review period of its biologics license application (BLA) for pegvaliase by three months to May 25, 2018.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Corcept Therapeutics, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)
Corcept Therapeutics (CORT) was a big mover last session, as the company saw its shares rise more than 10% on the day amid huge volumes.
Corcept Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Corcept Therapeutics rocketed Thursday after joining the S&P SmallCap 600, replacing Gigamon which is being acquired by Elliott Associates.
Allergan (AGN) and partner Paratek announces that its new drug application for Seysara has been accepted for review by the FDA for moderate to severe acne vulgaris.
NEW YORK , Dec. 20, 2017 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: S&P SmallCap 600 constituent Interactive Brokers Group Inc. (NASD:IBKR) ...
Regeneron Pharmaceuticals (REGN) and ISA Pharmaceuticals inked an agreement to advance ISA101 in combination with cemiplimab.
Alnylam (ALNY) and partner Sanofi have submitted a Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment adults with hereditary ATTR amyloidosis with polyneuropathy.
Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.
Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.